MaxCyte (MXCT) Stock Price, News & Analysis

Company Overview

MaxCyte, Inc. (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies. MaxCyte’s platform enables nonviral delivery with high efficiency, viability and scalability, making it suitable for academic institutions, biotechnology companies and pharmaceutical partners.

The core of MaxCyte’s offering is its Flow Electroporation system, which comprises benchtop research instruments and Good Manufacturing Practice (GMP)‐compliant processors tailored to different stages of therapeutic development. Researchers use MaxCyte’s instruments to transiently permeabilize cell membranes, facilitating the uptake of DNA, RNA, proteins or CRISPR/Cas9 components without compromising cell health. In addition to instrument sales, the company generates revenue through the sale of proprietary reagents, disposables and licensing agreements with biopharmaceutical collaborators seeking to harness the platform for novel cell therapy programs.

Founded in 1998 and headquartered in Gaithersburg, Maryland, MaxCyte maintains a global footprint with offices and service centers across North America, Europe and Asia. In July 2016, the company completed its initial public offering on the Nasdaq Stock Market. Under the leadership of President and Chief Executive Officer Doug Doerfler, MaxCyte continues to expand its customer base and partnerships with leading research institutions and pharmaceutical companies, positioning its technology at the forefront of next‐generation cell and gene therapy development.

Key Stats

• Today's Range: $0.82 to $0.86
• 50-Day Range: $0.68 to $0.89
• 52-Week Range: $0.64 to $2.86
• Volume: 395,332 shs
• Average Volume: 636,807 shs
• Market Capitalization: $90.70 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.50
• Consensus Rating: Hold

MaxCyte Stock Analysis - MarketRank™

MaxCyte scored higher than 41% of companies evaluated by MarketBeat, and ranked 597th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Hold

Consensus Rating

MaxCyte has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 2 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

MaxCyte has a consensus price target of $5.50, representing about 549.6% upside from its current price of $0.85.

Amount of Analyst Coverage

MaxCyte has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for MaxCyte are expected to grow in the coming year, from ($0.31) to ($0.28) per share.

Price to Book Value per Share Ratio

MaxCyte has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.24% of the float of MaxCyte has been sold short.

Short Interest Ratio / Days to Cover

MaxCyte has a short interest ratio ("days to cover") of 6.39.

Change versus previous month

Short interest in MaxCyte has recently decreased by 2.51%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MaxCyte does not currently pay a dividend.

Dividend Growth

MaxCyte does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for MaxCyte this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for MXCT on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, MaxCyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,215.00 in company stock.

Percentage Held by Insiders

3.30% of the stock of MaxCyte is held by insiders.

Percentage Held by Institutions

68.81% of the stock of MaxCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MXCT Stock Analysis - Frequently Asked Questions

How have MXCT shares performed this year?

MaxCyte's stock was trading at $1.55 at the start of the year. Since then, MXCT shares have decreased by 45.4% and is now trading at $0.8467.

How were MaxCyte's earnings last quarter?

MaxCyte, Inc. (NASDAQ:MXCT) posted its quarterly earnings results on Tuesday, March, 24th. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.02. The firm had revenue of $6.76 million for the quarter, compared to analysts' expectations of $9.16 million. MaxCyte had a negative trailing twelve-month return on equity of 22.15% and a negative net margin of 135.14%.
Read the conference call transcript.

When did MaxCyte IPO?

MaxCyte (MXCT) raised $150 million in an initial public offering on Friday, July 30th 2021. The company issued 12,000,000 shares at $11.50-$13.50 per share.

Who are MaxCyte's major shareholders?

Top institutional investors of MaxCyte include Capricorn Fund Managers Ltd (7.67%), Bank of New York Mellon Corp (0.38%) and Hsbc Holdings PLC (0.23%). Insiders that own company stock include Stanley C Erck, Douglas Doerfler, Richard Douglas, Maher Masoud, Douglas J Swirsky, William W Brooke, John Joseph Johnston, David I Sandoval, Ali Soleymannezhad, Rekha Hemrajani and Thomas M Ross.
View institutional ownership trends.

How do I buy shares of MaxCyte?

Shares of MXCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of MaxCyte own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MaxCyte investors own include Tesla (TSLA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Home Depot (HD).

Company Calendar

• Last Earnings: 3/24/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:MXCT
• CIK: 1287098
• Web: maxcyte.com
• Phone: 301-944-1700
• Fax: 301-944-1703
• Employees: 80
• Year Founded: 1998

Price Target and Rating

• Average Price Target for MaxCyte: $5.50
• High Price Target: $6.00
• Low Price Target: $5.00
• Potential Upside/Downside: +549.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.43)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$44.63 million
• Net Margins: -135.14%
• Pretax Margin: -135.14%
• Return on Equity: -22.15%
• Return on Assets: -18.98%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.30
• Quick Ratio: 7.77

Sales & Book Value

• Annual Sales: $33.03 million
• Price / Sales: 2.75
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.61 per share
• Price / Book: 0.53

Miscellaneous

• Outstanding Shares: 107,120,000
• Free Float: 103,587,000
• Market Cap: $90.70 million
• Optionable: Optionable
• Beta: 1.37